

<b>U. S. PATENT AND TRADEMARK OFFICE</b> <b>U.S. DEPARTMENT OF COMMERCE</b>		<b>ATTORNEY'S DOCKET NUMBER</b> 21562P
		<b>U.S. APPLICATION NO. (If known, see 37 CFR 1.5)</b> <b>10/573108</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES</b> <b>DESIGNATED/ELECTED OFFICE (DO/EO/US)</b> <b>CONCERNING A FILING UNDER 35 U.S.C. 371</b>	<b>INTERNATIONAL APPLICATION NO.</b> PCT/US2004/036252	<b>INTERNATIONAL FILING DATE</b> 29 October 2004
		<b>PRIORITY DATE CLAIMED</b> 04 November 2003
<b>TITLE OF INVENTION</b> FUSED PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES		
<b>APPLICANT(S) FOR DO/EO/US</b> Wallace T. Ashton, Hong Dong, Jinyou Xu		
<b>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</b>		
<ol style="list-style-type: none"><li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li>3. <input type="checkbox"/> This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.</li><li>4. <input checked="" type="checkbox"/> The US has been elected (PCT Article 31).</li><li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed [35 U.S.C. 371(c)(2)]<ol style="list-style-type: none"><li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li><li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li><li>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li></ol></li><li>6. <input type="checkbox"/> An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].<ol style="list-style-type: none"><li>a. <input type="checkbox"/> is attached hereto</li><li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li></ol></li><li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].<ol style="list-style-type: none"><li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li><li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li><li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li><li>d. <input type="checkbox"/> have not been made and will not be made.</li></ol></li><li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].</li><li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].</li><li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].</li></ol>		
<b>Items 11 to 20 below concern other document(s) or information included:</b>		
<ol style="list-style-type: none"><li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li><li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li><li>13. <input checked="" type="checkbox"/> A preliminary amendment.</li><li>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</li><li>15. <input type="checkbox"/> A substitute specification.</li><li>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</li><li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</li><li>18. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C.154(d)(4).</li><li>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).</li><li>20. <input type="checkbox"/> Other items or information:</li></ol>		

14P20R334357PTO 29 MAR 2006

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 2em; font-weight: bold; text-align: center;">10/573108</div>		INTERNATIONAL APPLICATION NO. PCT/US2004/036252		ATTORNEY'S DOCKET NUMBER 21562P	
--	--	--	--	------------------------------------	--

The following fees are submitted:

	CALCULATIONS	PTO USE ONLY								
21. <input checked="" type="checkbox"/> Basic national fee.....\$300	\$300.00									
22. <input checked="" type="checkbox"/> Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0 All other situations.....\$200	\$0.00									
23. <input checked="" type="checkbox"/> Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0 Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an International Searching Authority.....\$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB .....\$400 All other situations.....\$500	\$0.00									
<b>TOTAL OF 21, 22 and 23=</b>	<b>\$300.00</b>									
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:15%;">Total Sheets</th> <th style="width:15%;">Extra Sheets</th> <th style="width:30%;">Number of each additional 50 or fraction thereof (round up to a whole number)</th> <th style="width:40%;">RATE</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">60 - 100 =</td> <td style="text-align: center;">0 /50</td> <td style="text-align: center;">0 = 0</td> <td style="text-align: center;">X \$250.00</td> </tr> </tbody> </table>	Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE	60 - 100 =	0 /50	0 = 0	X \$250.00	\$0.00	
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE							
60 - 100 =	0 /50	0 = 0	X \$250.00							
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].										
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE							
Total Claims	20 - 20 =	0	X \$50.00							
Independent Claims	1 - 3 =	0	X \$200.00							
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00							
<b>TOTAL OF ABOVE CALCULATIONS (SUBTOTAL)</b>			<b>= \$300.00</b>							
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			+							
<b>TOTAL NATIONAL FEE</b>			<b>= \$300.00</b>							
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.			+							
<b>TOTAL FEES ENCLOSED</b>			<b>= \$300.00</b>							
		Amount to be refunded:								
		Amount to be charged:								

a. ☐ A check in the amount of \$ \_\_\_\_\_ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 13-2755 in the amount of \$300.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.**

SEND ALL CORRESPONDENCE TO:

Customer No. 000210

MERCK & CO., INC.  
 Patent Department, RY60-30  
 P.O. Box 2000  
 126 East Lincoln Avenue  
 Rahway, New Jersey 07065-0970

SIGNATURE

Philippe L. Durette  
 NAME

35,125  
 REGISTRATION NUMBER

DATE: March 23, 2006

PHONE #: (732) 594-4568

100/07/5108  
AP20 Rec'd 23 MAR 2006

**Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING  
A FILING UNDER 35 U.S.C. 371**

**Attorney Docket No.:** 21562P

**International Appln No.:** PCT/US2004/036252

**International Filing Date:** 29 October 2004

**Priority Date:** 04 November 2003

**Title:** FUSED PHENYLALANINE DERIVATIVES AS  
DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE  
TREATMENT OR PREVENTION OF DIABETES

**Inventors:** Wallace T. Ashton, Hong Dong, Jinyou Xu

**EXPRESS MAIL CERTIFICATE**

**DATE OF DEPOSIT** March 23, 2006

**EXPRESS MAIL NO.** EL 989584906 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS  
EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE  
DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR  
PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY

*Kathy Klutowski*

DATE

3-23-06